Common Antidepressant Shows Significant Promise Easing Long COVID Fatigue
A low-cost antidepressant drug called fluvoxamine significantly reduced fatigue and improved quality of life in people struggling with long COVID symptoms, offering the first meaningful pharmacological intervention for this disabling condition.
Fluvoxamine Provides Breakthrough for Long COVID Sufferers
A low-cost antidepressant may offer new hope for people struggling with long COVID fatigue. Long COVID—the persistent symptoms some people experience weeks or months after initial COVID-19 infection—has posed a major challenge for healthcare providers, as no effective treatments have been widely validated.
Clinical Trial Results
In a randomized clinical trial involving 399 adults, fluvoxamine significantly reduced fatigue and improved quality of life compared with a placebo, making it one of the first medications to show meaningful benefits for this disabling condition. The trial's size and design provide substantial evidence that fluvoxamine's benefits are real rather than placebo effects.
Why Fatigue Matters in Long COVID
Fatigue ranks among the most debilitating long COVID symptoms, often rendering previously active individuals unable to work or care for themselves. This "post-exertional malaise"—where physical or mental effort worsens symptoms—has confounded standard rehabilitation approaches. The discovery that an affordable, widely available medication can significantly improve this symptom represents a major clinical breakthrough.
Cost and Accessibility Advantages
Fluvoxamine is an established selective serotonin reuptake inhibitor (SSRI) that has been used safely for decades to treat depression and anxiety. Its low cost and established safety profile mean it can be rapidly integrated into clinical practice without the lengthy approval processes required for new drugs. This accessibility could benefit millions globally who struggle with long COVID's lingering fatigue. Further research will explore optimal dosing for long COVID patients and whether the drug benefits other long COVID symptoms beyond fatigue.